Medical Licensing (MD/DO) · Independent exam preparation
Certification Examination in Neuromuscular Medicine Study Guide
Practise neuromuscular localization, electrodiagnostic interpretation, genetic reasoning, and treatment decisions for the ABPMR physician subspecialty pathway.
By CertMedbry · Updated 16 October 2026
Localize weakness, distinguish treatable mimics, interpret electrodiagnostic findings, and connect disease mechanisms with management decisions. This selective guide develops 60 substantive concepts across all nine disorder domains. The official ABPN detailed content outline defines the full examination scope; candidates should study its remaining topics as well as these selections.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide address?
The ABPMR initial-certification pathway is intended for ABPMR diplomates meeting its licensure and fellowship requirements. The credential is physician subspecialty board certification. The shared examination also serves eligible ABPN neurologists and child neurologists, whose board-specific eligibility rules differ.
ABPMR — Neuromuscular Medicine · ABPN — Neuromuscular Medicine
How many questions are there, and how long is testing?
The official blueprint specifies 220 questions. The issuers' timing descriptions differ: ABPMR summarizes one four-hour section, no scheduled break, and four hours of active testing plus a tutorial. ABPN's linked format document, revised November 30, 2023, instead describes four sections of 55 questions, 230 minutes for questions, and optional between-section breaks during which examination time continues. Its 240-minute total includes five minutes for the NDA and instructions and five minutes for the survey. These descriptions are not conclusively reconciled. Follow your administration-specific scheduling and examination instructions, and contact your board if they conflict. Research or pretest items may be unscored; 220 is not established as the scored-item count.
ABPMR — Neuromuscular Medicine · Neuromuscular Medicine Certification Content Specifications · Neuromuscular_Medicine_CERT_Format_and_Scoring.pdf
Where is the examination delivered, what item styles are documented, and is it adaptive?
ABPMR identifies Pearson Professional Centers nationwide as examination locations. ABPN's linked format document, revised November 30, 2023, describes computer-delivered, stand-alone, one-best-answer multiple-choice questions that can be skipped or flagged for review. It does not establish adaptive delivery or specify the number of answer options. This guide's four-option practice questions do not establish either feature of the operational examination. Consult administration-specific instructions for current interface and review rules.
ABPMR — Neuromuscular Medicine · ABPN — Neuromuscular Medicine · Neuromuscular_Medicine_CERT_Format_and_Scoring.pdf
Which blueprint and examination window apply?
The official initial-certification pages list October 19–23, 2026. The linked 15-page content specifications are dated December 1, 2025; no separate effective date is stated. Clinical-reference publication dates do not identify the examination blueprint version.
ABPMR — Neuromuscular Medicine · ABPN — Neuromuscular Medicine · Neuromuscular Medicine Certification Content Specifications
How are disorder domains weighted?
Dimension 1 assigns Motor neuron disorders 15–18%; Spinal root disorders 4–6%; Plexopathies 4–6%; Peripheral nerve disorders 24–26%; Neuromuscular junction transmission disorders 16–20%; Muscle disorders 24–26%; Hyper-excitability disorders 1–3%; Autonomic dysfunction in neuromuscular diseases 1–3%; and Questions not associated with a specific neuromuscular disorder 1–2%. These are published ranges. This guide approximates their emphasis while preserving every domain; small question and flashcard sets necessarily require rounding.
How does the competency dimension affect preparation?
Dimension 2 overlaps the disorder domains: neuroscience/mechanism 7–13%, clinical aspects 35–41%, diagnostic procedures 21–27%, treatment/management 17–23%, and communication, professionalism, practice-based learning, and systems-based practice each 1–3%. Every examination item links a disorder/topic with a competency/mechanism. These percentages are not additional disorder allocations. The weight table uses Spinal root disorders; the detailed outline expands that section to Spinal root/cord disorders.
How do ABPMR and ABPN eligibility rules differ?
For the listed ABPMR pathway, candidates need ABPMR diplomate status, qualifying unrestricted medical licensure, and 12 months of qualifying ACGME-accredited fellowship training completed by August 31 before the examination. ABPN's listed pathway requires its qualifying neurology certification and fellowship requirements, with training completed by July 31 of the examination year. The historical ABPN practice pathway applied during 2008–2012 and should not be treated as a current alternative.
ABPMR — Neuromuscular Medicine · ABPN — Neuromuscular Medicine
This guide addresses initial physician subspecialty certification through ABPMR in the shared Certification Examination in Neuromuscular Medicine. ABPMR credentials its diplomates and awards their certificates; ABPN develops and administers the examination. These independently authored educational materials are not official examination items.
Outline used: Current ABPN Neuromuscular Medicine Certification Content Specifications, dated December 1, 2025, linked from the official initial-certification page for the October 19–23, 2026 examination. The document does not state a separate effective date. Verified on October 9, 2026. The workbook label identifies the ABPMR certification pathway to this shared examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Motor neuron disorders15–18%
1.How do an ALS pattern and the Gold Coast diagnostic criteria differ?
Combined upper and lower motor neuron signs suggest an ALS pattern, but the Gold Coast criteria are operational: progressive motor impairment after previously normal motor function; upper and lower motor neuron dysfunction in at least one region, both in the same region when only one is involved, or lower motor neuron dysfunction in at least two regions; and investigations excluding another disease process. Regions are bulbar, cervical, thoracic, and lumbosacral. Lower motor neuron regional involvement requires abnormalities in two limb muscles supplied by different roots and nerves, or one bulbar or thoracic muscle. Lower motor neuron dysfunction is clinical weakness with wasting, or EMG evidence of both chronic neurogenic change and ongoing denervation, including fibrillation potentials, positive sharp waves, or fasciculation potentials.
Apply it
A patient has progressive weakness and wasting with qualifying active and chronic neurogenic EMG changes in cervical and lumbosacral regions but no demonstrated upper motor neuron signs. The lower-motor-neuron-in-two-regions pathway can satisfy Gold Coast criteria if alternative diseases are excluded.
Common pitfall: Absence of demonstrated upper motor neuron dysfunction does not automatically exclude ALS under Gold Coast criteria. Conversely, isolated fasciculations or nonspecific denervation do not satisfy the complete criteria.
2.How does needle EMG demonstrate lower motor neuron injury?
Needle EMG evaluates both ongoing denervation and chronic motor unit remodeling. Fibrillation potentials and positive sharp waves indicate denervated muscle fibers, while enlarged, prolonged motor unit potentials with reduced recruitment support chronic neurogenic change. Fasciculation potentials acquire diagnostic significance in the appropriate neurogenic context. Sampling multiple anatomical regions helps establish disease distribution, but electrical abnormalities must still be interpreted alongside clinical progression and alternative causes of motor axon injury.
Apply it
A weak hand muscle shows fibrillations and large motor units. Similar changes in a clinically less affected leg broaden the localization beyond one injured nerve, prompting assessment for a more widespread motor neuron process.
Common pitfall: Denervation is not specific to ALS. Radiculopathy, focal nerve injury, and other axonal disorders can produce the same abnormalities in their anatomical distributions.
3.When should a motor neuropathy interrupt an ALS diagnosis?
Multifocal motor neuropathy can resemble a lower motor neuron syndrome because it causes asymmetric weakness with little or no objective sensory loss. Motor conduction block outside typical entrapment sites is an important discriminating finding. Weakness following named nerves rather than a diffuse regional pattern also supports this alternative. The distinction matters because IVIg has evidence of benefit in multifocal motor neuropathy, whereas the presence of weakness and fasciculations alone does not distinguish it from ALS.
Apply it
A patient has asymmetric finger-extension weakness without spasticity or sensory loss. Motor studies demonstrate reproducible conduction block in a noncompressible nerve segment, shifting the working diagnosis toward an immune-mediated motor neuropathy and a treatable pathway.
Common pitfall: Normal sensory studies do not distinguish ALS from multifocal motor neuropathy. Both may spare sensory responses; conduction block and the clinical distribution provide stronger discrimination.
Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies · Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders
4.How does SMN1 testing establish common 5q SMA?
Common 5q spinal muscular atrophy results from biallelic pathogenic variants affecting SMN1 and is inherited in an autosomal recessive pattern. Reduced survival motor neuron protein causes degeneration of lower motor neurons, producing symmetric weakness and reduced reflexes without a primary sensory syndrome. Molecular testing should address SMN1 copy number and, when indicated, sequence variants. A compatible phenotype with only one detected pathogenic allele warrants further molecular evaluation rather than automatic exclusion.
Apply it
An infant has hypotonia, proximal weakness, and absent reflexes with preserved social interaction. Testing identifies one SMN1 deletion; the next diagnostic step includes looking for a pathogenic sequence variant on the other allele.
Common pitfall: A single identified deletion does not establish a recessive diagnosis by itself. Conversely, deletion-only testing can miss an affected person carrying a sequence variant.
5.Why does SMN2 copy number modify SMA severity?
SMN2 differs from SMN1 in a way that promotes exclusion of exon 7 from most transcripts, limiting production of full-length functional SMN protein. Additional SMN2 copies generally increase residual protein and are associated with milder disease. This relationship is useful for prognosis and treatment planning but is not an exact prediction for an individual. Clinical status, age, and other modifiers remain important, particularly when deciding how urgently to intervene.
Apply it
Two siblings have biallelic SMN1 loss but different SMN2 copy counts and motor abilities. Explain that copy number helps account for the difference without guaranteeing either child's future walking, respiratory function, or treatment response.
Common pitfall: SMN2 copy number modifies disease; it does not replace SMN1-based diagnosis or justify delaying assessment in an infant who currently appears clinically well.
6.How do SMN-directed therapies address SMA biology?
SMN-directed treatments increase functional survival motor neuron protein through different mechanisms. Nusinersen and risdiplam modify SMN2 splicing to increase full-length protein, while SMN1 gene replacement supplies a functional gene copy. Their shared biological goal does not make their administration, eligibility, monitoring, or risks interchangeable. Early treatment is important because improving protein production cannot reliably restore motor neurons already lost. Respiratory, nutritional, orthopedic, and rehabilitation care remain necessary alongside molecular treatment.
Apply it
A newborn-screened infant has molecularly confirmed SMA but no obvious weakness. Arrange prompt specialist treatment assessment and baseline multidisciplinary evaluation rather than waiting for motor regression to demonstrate that the genetic result is clinically meaningful.
Common pitfall: A disease-modifying treatment does not eliminate supportive care needs. Apparent motor improvement can coexist with swallowing, respiratory, or musculoskeletal complications requiring separate assessment.
7.Why is noninvasive ventilation important in ALS?
Respiratory muscle weakness in ALS reduces effective ventilation, often first during sleep. Noninvasive ventilation supports alveolar ventilation and can improve symptoms, quality of life, and survival in appropriate patients. The randomized trial demonstrated its clearest survival benefit in participants without severe bulbar dysfunction; severe bulbar involvement affects tolerance and expected benefit. Decisions should integrate orthopnea, morning headache, sleep disruption, cough effectiveness, serial vital capacity and inspiratory strength, interface tolerance, secretion management, and patient preferences. Bulbar weakness can impair the mouth seal and test reliability, requiring alternative respiratory measurements or sleep-related assessment.
Apply it
A person with ALS reports morning headaches and difficulty lying flat despite comfortable daytime breathing. Discuss nocturnal ventilatory assessment and noninvasive ventilation, including realistic benefits, interface options, and how secretion problems could affect successful use. Inconsistent spirometry from a poor mouth seal should not override these symptoms.
Common pitfall: Supplemental oxygen alone does not correct neuromuscular hypoventilation. A reassuring oxygen saturation or unreliable spirometry cannot exclude inadequate ventilation, especially during sleep or early respiratory decline.
Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial · NICE NG42 — Motor neurone disease: assessment and management
8.How should disease-modifying pharmacotherapy be discussed at ALS diagnosis?
The 2024 EAN guideline recommends riluzole at diagnosis, usually 50 mg twice daily. Randomized evidence supports a modest survival benefit; treatment does not restore lost strength or cure ALS. Obtain baseline aminotransferases and monitor monthly for the first three months and periodically thereafter because hepatic injury can occur. These monitoring requirements are specified in the [riluzole prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dd432c13-389e-46b3-8891-0cf1a58800ff). Genotype can change treatment: intrathecal tofersen reduces SOD1 mRNA and protein. Its [U.S. indication](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=81356b45-1cb7-4eef-88ea-e44cc18b47c5) covers adults with ALS and an SOD1 mutation under accelerated approval based on reduced plasma neurofilament light. This surrogate-based approval differs from proof of clinical benefit on every outcome. EAN recommends offering tofersen for progressive ALS caused by a pathogenic SOD1 variant, with discussion of serious adverse effects and treatment burden.
Apply it
Offer a newly diagnosed patient riluzole with baseline liver testing and a monitoring plan. A pathogenic SOD1 result additionally prompts a tofersen discussion. Explain anticipated benefit, uncertainty, repeated intrathecal administration, and how access and patient priorities affect the decision.
Common pitfall: A regulatory indication, a guideline recommendation, and a clinical trial's eligibility criteria answer different questions. An asymptomatic SOD1 carrier does not meet the stated ALS treatment indication merely by carrying the variant, and trial participation requires that study's own criteria.
9.When should swallowing and nutrition be addressed in ALS?
Bulbar weakness can impair bolus control, airway protection, and efficient oral intake. Weight loss may also reflect prolonged meals, fatigue, or increased energy requirements rather than choking alone. Assessment should therefore consider swallowing safety, hydration, nutrition, meal duration, and respiratory status together. Discussing gastrostomy early allows informed planning before severe respiratory compromise or an urgent nutritional crisis limits options. Feeding support complements, rather than automatically replaces, individualized decisions about oral intake.
Apply it
A patient denies choking but has lost weight and needs an hour to finish meals. Arrange swallowing and dietary assessment, explore fatigue and food consistency, and begin a discussion about future feeding support while communication remains effective.
Common pitfall: Waiting for aspiration pneumonia misses earlier nutritional indications for intervention. Absence of reported choking does not demonstrate adequate intake or exclude impaired swallowing safety.
NICE NG42 — Motor neurone disease: assessment and management
10.How should communication support preserve decision-making in ALS?
Progressive dysarthria can restrict expression without eliminating understanding or decision-making capacity. Early assessment for augmentative and alternative communication allows the person to learn suitable tools before speech or hand function deteriorates. Access methods should anticipate changing motor abilities, including possible eye-gaze use. Communication support also enables informed discussion of ventilation, nutrition, and future care preferences. Capacity should be assessed for the particular decision and must not be inferred from speech clarity.
Apply it
A patient speaks slowly but demonstrates consistent understanding and preferences through a tablet. Address treatment choices directly to the patient, allow adequate response time, and arrange an access review before hand weakness makes the current device difficult.
Common pitfall: Severe dysarthria is not equivalent to incapacity. Letting relatives answer automatically can silence a capable patient and obscure preferences that appropriate communication support would reveal.
NICE NG42 — Motor neurone disease: assessment and management
Spinal root disorders4–6%
11.Why are sensory responses often preserved in radiculopathy?
A typical root lesion is proximal to the dorsal root ganglion. The distal sensory axon and its cell body remain intact, so routine distal sensory nerve action potentials are often preserved despite dermatomal sensory symptoms. This preganglionic relationship helps distinguish radiculopathy from postganglionic plexus or peripheral nerve disease. It is a localization principle rather than an absolute rule: coexisting neuropathy, technical factors, and lesions involving the ganglion can alter expected sensory findings.
Apply it
A patient has radiating neck pain and thumb numbness with a preserved median sensory response. Combine myotomal weakness and needle findings with imaging rather than excluding a cervical root lesion because the sensory study is normal.
Common pitfall: Normal sensory nerve conduction does not mean sensory symptoms are nonneurologic. Routine testing evaluates distal axons and may remain normal in a preganglionic root lesion.
12.How does muscle selection strengthen root localization?
A root supplies muscles through several peripheral nerves. Neurogenic abnormalities in muscles sharing a root contribution but supplied by different nerves support myotomal localization more strongly than abnormalities confined to one named nerve. Paraspinal sampling can provide additional evidence because these muscles receive innervation before plexus formation. Overlapping root supply, lesion severity, timing, and prior spine procedures limit interpretation. A normal examination can occur in early, mild, or sensory-predominant radiculopathy because needle EMG detects motor axon consequences.
Apply it
Elbow flexion and wrist extension are weak. Select muscles supplied by different peripheral nerves with overlapping suspected root contributions, and consider paraspinals, instead of sampling only several muscles within the same distal nerve territory.
Common pitfall: One abnormal muscle cannot reliably distinguish a root lesion from a peripheral nerve lesion. A normal early study also cannot exclude a clinically convincing sensory-predominant root lesion.
13.Which findings require a cervical cord explanation rather than isolated radiculopathy?
A cervical root lesion can produce segmental weakness, pain, and reflex loss, but it does not explain upper motor neuron signs in the legs. Hand weakness accompanied by spastic gait, pathological plantar responses, or a sensory level raises concern for cervical cord involvement. Cord compression can coexist with root injury, creating lower motor neuron signs at the affected level and upper motor neuron signs below it. Cervical imaging must be matched to the examination; incidental degenerative findings alone do not establish the cause.
Apply it
A patient referred for hand numbness also has leg stiffness, impaired tandem gait, and bilateral extensor plantar responses. Assess for cervical myelopathy and obtain appropriate spinal imaging rather than limiting the evaluation to carpal tunnel syndrome or one cervical root.
Common pitfall: A normal distal sensory response does not distinguish a root lesion from a central cord disorder. Long-tract signs and the distribution of sensory abnormalities provide the crucial additional localization.
Neuromuscular Medicine Certification Content Specifications · Supplementary tables including criteria for diagnosing ALS · AANEM — Cervical Radiculopathy/Brachial Plexopathy
Plexopathies4–6%
14.Which findings favor plexopathy over radiculopathy?
Plexus lesions are usually postganglionic, so affected distal sensory responses may be reduced. Weakness can span several terminal nerves while following a trunk, division, or cord distribution. In an isolated plexopathy, paraspinal muscles are generally spared because their innervation branches before the plexus. None of these findings should stand alone: compare sensory amplitudes, sample anatomically informative muscles, and consider technical limitations or a coexisting neuropathy before deciding that the lesion is plexal.
Apply it
Shoulder and elbow weakness spans several nerves, sensory responses are reduced in the affected distribution, and cervical paraspinals are normal. This combination supports a plexus localization more strongly than an isolated cervical root lesion.
Common pitfall: Normal paraspinals alone do not prove plexopathy. Root lesions can escape sampling, and sensory amplitudes require technically sound interpretation with the patient's broader nerve-conduction pattern.
15.What sequence suggests neuralgic amyotrophy?
Neuralgic amyotrophy typically begins with severe acute shoulder or arm pain followed by patchy weakness and atrophy. The distribution may involve selected nerves or fascicles rather than a tidy single-root pattern. Pain can improve while motor deficits become more apparent, so the sequence is diagnostically useful. High-resolution ultrasound can demonstrate focal enlargement, fascicular abnormalities, or hourglass-like constrictions corresponding to persistent deficits. Imaging complements clinical and electrodiagnostic localization and may also investigate competing structural explanations.
Apply it
After several nights of intense shoulder pain, a patient notices scapular winging and difficulty forming a thumb–index pinch. The patchy deficits and pain-to-weakness sequence prompt evaluation for neuralgic amyotrophy rather than isolated rotator-cuff disease.
Common pitfall: Improving pain does not establish recovery of the nerve lesion. A normal ultrasound also does not exclude neuralgic amyotrophy.
16.Which pattern suggests diabetic lumbosacral radiculoplexus neuropathy?
Diabetic lumbosacral radiculoplexus neuropathy often begins with substantial unilateral hip or thigh pain followed by weakness and wasting that can spread beyond one root or peripheral nerve. Weight loss and subsequent involvement of the other leg can accompany the course. Roots, plexus, and peripheral nerves may be involved, so paraspinal abnormalities do not exclude it. A [prospective clinicopathological study](https://pubmed.ncbi.nlm.nih.gov/10599791/) demonstrated multifocal axonal loss and ischemic injury associated with microvasculitic changes, including vascular inflammation and vessel-wall damage. This painful, asymmetric proximal syndrome differs from ordinary distal symmetric diabetic polyneuropathy and requires evaluation for structural or neoplastic alternatives.
Apply it
An adult with diabetes develops severe thigh pain, weight loss, quadriceps wasting, and weakness extending into additional nerve territories. Investigate a lumbosacral radiculoplexus process while assessing for compressive, pelvic, or malignant explanations rather than attributing everything to routine diabetic distal neuropathy.
Common pitfall: Diabetes does not make every neuropathic presentation length dependent. Evidence of a microvasculitic mechanism does not, by itself, establish the effectiveness of a particular immunotherapy.
Peripheral nerve disorders24–26%
17.When does conduction slowing meet an operational demyelinating threshold?
The 2021 EAN/PNS CIDP criteria include motor conduction velocity at least 30% below the laboratory lower limit of normal in at least two nerves as one strongly supportive motor demyelinating criterion. If the lower limit is 50 m/s for each tested segment, velocities of 34 and 35 m/s meet that numerical threshold; 40 m/s does not. Testing requires adequate temperature, accurate distances, supramaximal stimulation, and correct onset measurements. Slowing confined to common compression segments, such as the ulnar nerve across the elbow or fibular nerve across the knee, should not be counted as generalized demyelination. Severe axonal loss and very low distal responses require particular caution.
Apply it
A patient has velocities of 34 and 35 m/s in two appropriately tested non-entrapment segments with laboratory lower limits of 50 m/s. Recognize that this motor criterion is met, then evaluate the clinical course, sensory criteria, additional studies, and competing diagnoses before diagnosing CIDP.
Common pitfall: An isolated numerical threshold does not establish CIDP. Cooling, technical error, focal entrapment, and amplitude-dependent slowing can mimic demyelination; the full clinical and electrodiagnostic framework remains necessary.
EAN/PNS guideline on diagnosis and treatment of CIDP — Second revision
18.Which clinical course and supporting tests favor typical CIDP?
Typical CIDP produces progressive or relapsing symmetric proximal and distal weakness, sensory involvement, and reduced or absent reflexes over at least eight weeks. Clinical features must align with electrodiagnostic evidence and exclusion of mimics. Distal-only, asymmetric, sensory, and motor presentations require consideration of variants and alternatives. Elevated CSF protein is supportive but nonspecific; age, diabetes, and other neurological conditions affect interpretation. Protein elevation cannot replace appropriate nerve-conduction findings, and unexpected cellular abnormalities should prompt evaluation for infectious, inflammatory, or neoplastic alternatives.
Apply it
A patient has three months of worsening stair climbing, hand weakness, distal numbness, and areflexia. Evaluate for CIDP with nerve-conduction testing while checking whether hereditary, metabolic, or paraproteinemic disease better accounts for the complete presentation. Mild CSF protein elevation in an older adult with diabetes should not drive the diagnosis.
Common pitfall: Any neuropathy lasting eight weeks is not CIDP. Chronicity or a nonspecific supportive test cannot compensate for an incompatible phenotype or electrophysiological pattern.
EAN/PNS guideline on diagnosis and treatment of CIDP — Second revision
19.How does CMT1A differ from HNPP and acquired demyelinating neuropathy?
PMP22 duplication causes CMT1A, whereas a heterozygous PMP22 deletion commonly causes HNPP. CMT1A typically produces a chronic distal neuropathy with relatively uniform conduction slowing across nerves and segments; HNPP emphasizes recurrent focal pressure palsies. Acquired inflammatory neuropathy more often shows nonuniform abnormalities, including temporal dispersion or conduction block outside entrapment sites, interpreted with the clinical course. A [CMT1A cohort study](https://pmc.ncbi.nlm.nih.gov/articles/PMC3391619/) demonstrated uniform slowing and found disability related more closely to motor response amplitudes than conduction velocity, emphasizing the contribution of axonal loss.
Apply it
A patient with longstanding distal weakness and foot deformity has similarly slow velocities across several nerves. Review the pedigree and consider PMP22 copy-number testing before labeling the slowing CIDP. A history of episodic compression palsies instead favors HNPP.
Common pitfall: Uniform slowing is a useful CMT1A clue, not a universal rule for every hereditary neuropathy. A demyelinating-range velocity alone does not establish an acquired immune mechanism.
GeneReviews — Hereditary Neuropathy with Liability to Pressure Palsies · Neuromuscular Medicine Certification Content Specifications · EAN/PNS guideline on diagnosis and treatment of CIDP — Second revision
20.How should initial CIDP treatment be selected and assessed?
IVIg or corticosteroids are recommended initial treatments for typical CIDP and appropriate variants, while plasma exchange is recommended when those options are ineffective. Selection considers phenotype, comorbidities, adverse effects, access, and patient preferences. IVIg should be considered initially in motor CIDP because some patients deteriorate with corticosteroids; distinguish symmetric proximal-distal motor CIDP from the asymmetric named-nerve pattern of MMN. Document objective impairment and disability before treatment so benefit can be assessed reproducibly. Individualize maintenance and periodically evaluate whether treatment intensity can be reduced.
Apply it
Before starting therapy for confirmed CIDP, record grip strength and a functional disability measure relevant to the patient's limitations. Reassess the same measures after treatment. Severe osteoporosis or poorly controlled diabetes may favor IVIg over corticosteroids; a motor-only phenotype also changes that discussion.
Common pitfall: A temporary subjective boost does not validate the diagnosis. Objective change and the complete clinical evidence should guide ongoing treatment rather than indefinite continuation by default.
EAN/PNS guideline on diagnosis and treatment of CIDP — Second revision
21.Which combination should prompt evaluation for amyloid neuropathy?
Progressive axonal sensorimotor neuropathy with autonomic dysfunction, unexplained weight loss, bilateral carpal tunnel syndrome, or cardiac hypertrophy should raise concern for amyloidosis. Hereditary ATTR disease results from pathogenic TTR variants and misfolded transthyretin deposition; light-chain amyloidosis requires a different hematologic evaluation and treatment pathway. The [ATTR diagnostic consensus](https://pmc.ncbi.nlm.nih.gov/articles/PMC7513485/) emphasizes these red flags, TTR sequencing when appropriate, and accurate typing of tissue amyloid. Congo-red-positive deposits establish amyloid but do not alone identify its precursor protein; mass spectrometry can establish the deposited protein.
Apply it
A patient labeled as having atypical CIDP has progressive axonal loss, orthostatic symptoms, bilateral carpal tunnel operations, and unexplained cardiac thickening. Reassess for amyloidosis and coordinate neurologic, cardiac, genetic, and hematologic investigations rather than escalating immunotherapy solely for continued decline.
Common pitfall: A monoclonal protein does not by itself prove light-chain amyloid deposition. A negative family history also does not exclude hereditary ATTR disease; the phenotype and accurate amyloid typing remain decisive.
22.Which pattern identifies multifocal motor neuropathy and changes treatment?
Multifocal motor neuropathy typically causes slowly progressive or stepwise asymmetric weakness, often prominent in distal upper limbs, with little or no objective sensory loss. Weakness follows individual motor nerve territories, and conduction block outside common compression sites is a key electrophysiological clue. Anti-GM1 antibodies can support the diagnosis but are not required. IVIg has supporting treatment evidence; corticosteroids and plasma exchange are not established substitutes. Document objective strength and disability because ongoing axonal loss may limit reversibility even after immune activity is treated.
Apply it
A patient develops uneven finger and wrist weakness across two upper-limb nerve territories while sensation remains intact. Study relevant motor segments beyond standard entrapment sites, then use objective motor outcomes when assessing an evidence-supported IVIg treatment course.
Common pitfall: A negative anti-GM1 result does not exclude MMN. Neither sensory sparing nor an immune mechanism makes its diagnosis or treatment interchangeable with ALS or typical CIDP.
Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies · Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders
23.How is median neuropathy at the wrist distinguished from a cervical root lesion?
Median neuropathy at the wrist commonly causes nocturnal paresthesias in the thumb, index, middle, and radial ring finger, with thenar weakness in more advanced disease. Electrodiagnostic localization depends on focal median slowing across the wrist, often demonstrated by comparison with neighboring sensory nerves over matched distances. A cervical root lesion instead may cause myotomal weakness across different nerves while preserving distal sensory responses. Slowing at one entrapment site does not establish a generalized demyelinating neuropathy, and simultaneous root and median nerve disease remains possible.
Apply it
A patient reports waking with hand tingling relieved by shaking the hand. Median sensory conduction is disproportionately slow across the wrist compared with an adjacent nerve. Localize the finding to the wrist while checking for proximal weakness or long-tract signs that would require an additional explanation.
Common pitfall: A hand symptom diagram or isolated prolonged median latency is insufficient by itself. Temperature, generalized neuropathy, comparative studies, and the clinical distribution affect interpretation.
zivkovic-et-al-2020-muscle-nerve.pdf · AANEM — Cervical Radiculopathy/Brachial Plexopathy
24.How does the time course guide GBS assessment?
GBS is an acute polyradiculoneuropathy characterized by rapidly progressive weakness, usually with reduced reflexes, reaching its nadir within four weeks in the usual diagnostic framework. Sensory, cranial, respiratory, and autonomic manifestations can accompany weakness. The syndrome requires attention to progression and complications rather than waiting for every supportive test. Continued progression beyond eight weeks or repeated deterioration should prompt reconsideration of acute-onset CIDP and other explanations rather than automatic acceptance of a prolonged monophasic illness.
Apply it
A patient develops ascending weakness over six days after a gastrointestinal illness. Arrange urgent assessment of respiratory, bulbar, and autonomic function while pursuing diagnostic testing, rather than waiting for the weakness to reach a final plateau.
Common pitfall: GBS is not defined by ascending weakness alone. Reflexes, chronology, distribution, associated findings, and exclusion of spinal cord or other mimics determine the diagnostic interpretation.
EAN/PNS Guideline on diagnosis and treatment of Guillain–Barré syndrome
25.When can early GBS investigations be nondiagnostic?
The characteristic CSF pattern in GBS is elevated protein without a substantial cellular response, but protein may remain normal early in the illness. Electrodiagnostic abnormalities can also evolve, so an initially nondiagnostic study does not exclude a convincing acute syndrome. Repeat testing may clarify the pattern when clinically appropriate. Conversely, marked pleocytosis or an incompatible examination should trigger investigation of alternatives rather than being explained away as a routine feature of GBS.
Apply it
On the third day of progressive areflexic weakness, CSF protein is normal. Maintain clinical surveillance and the diagnostic differential, recognizing that the timing limits the test's sensitivity and that respiratory deterioration cannot await laboratory confirmation.
Common pitfall: Albuminocytologic dissociation is supportive rather than mandatory at presentation. Treating an early normal protein result as exclusionary can delay recognition of a clinically important acute neuropathy.
EAN/PNS Guideline on diagnosis and treatment of Guillain–Barré syndrome
26.Who should receive GBS immunotherapy, and within what treatment windows?
The 2023 EAN/PNS guideline recommends IVIg for patients unable to walk unaided within two weeks of weakness onset, using 0.4 g/kg/day for five days, and advises considering IVIg during weeks two to four. Plasma exchange is recommended within four weeks for patients unable to walk unaided. Despite preserved walking, treatment should be considered with rapid progression or important bulbar, respiratory, or autonomic involvement. Corticosteroids are not effective disease-directed treatment. Routine plasma exchange followed immediately by IVIg is not recommended, and predicted poor prognosis alone does not justify an automatic second IVIg course. Immunotherapy accompanies respiratory and autonomic surveillance, immobility care, and rehabilitation.
Apply it
A patient cannot walk independently eight days after weakness began. Offer either standard IVIg or plasma exchange after evaluating contraindications. An ambulatory patient with rapidly worsening swallowing and respiratory function also warrants urgent treatment consideration and monitored care.
Common pitfall: Independent walking is not reassurance when respiratory, bulbar, or autonomic function is deteriorating. Poor prognosis is different from a documented treatment-related fluctuation; worsening requires clinical reassessment rather than automatic treatment repetition.
EAN/PNS Guideline on diagnosis and treatment of Guillain–Barré syndrome
27.What genetic pattern explains recurrent pressure palsies, and how can risk be reduced?
Hereditary neuropathy with liability to pressure palsies commonly results from a heterozygous deletion involving PMP22 and follows autosomal dominant inheritance. Myelin vulnerability produces recurrent focal deficits after modest compression or stretch, often at entrapment sites; electrophysiology may reveal abnormalities beyond the symptomatic nerve. Prevention includes avoiding prolonged elbow pressure, leg crossing, and repetitive compression, using protective padding or suitable orthoses, and communicating vulnerability during surgical positioning. A negative family history does not exclude the disorder.
Apply it
A young adult develops foot drop after prolonged squatting and recalls a wrist palsy after sleeping on an arm. Investigate inherited compression susceptibility, review preventable exposures, and communicate positioning needs before a planned operation.
Common pitfall: Recovery from a prior palsy does not remove inherited susceptibility. PMP22 deletion-associated HNPP also should not be confused with the duplication classically associated with CMT1A.
GeneReviews — Hereditary Neuropathy with Liability to Pressure Palsies
28.Why should painful mononeuropathy multiplex raise concern for vasculitic neuropathy?
Acute or subacute painful deficits affecting separate named nerves suggest mononeuropathy multiplex. Vasculitic vessel injury produces ischemic axonal loss, often with asymmetric sensory and motor deficits accumulating stepwise. Low amplitudes and denervation support axonal injury. The [PNS vasculitic-neuropathy guideline](https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1529-8027.2010.00281.x) requires vessel-wall inflammation accompanied by vascular damage for pathologically definite vasculitic neuropathy. Perivascular inflammation alone is insufficient. Asymmetric fiber loss, active axonal degeneration, hemosiderin, vascular immune deposits, and adjacent muscle infarction can support a probable pathological classification. Assess systemic organ involvement and select an involved nerve, sometimes with adjacent muscle, when biopsy is indicated.
Apply it
A patient develops painful foot drop followed by weakness and numbness in an unrelated hand nerve territory. Investigate a multifocal axonal process and systemic disease. If biopsy shows inflammatory cells, determine whether they invade and damage a vessel wall before interpreting the finding as definite vasculitis.
Common pitfall: Neither pain and asymmetry nor isolated perivascular inflammation proves vasculitis. Absence of known systemic vasculitis does not exclude nerve-limited disease; infectious and neoplastic mimics still require consideration.
29.How can small fiber neuropathy be demonstrated despite normal nerve-conduction studies?
Routine nerve-conduction studies primarily assess large myelinated sensory and motor axons. Small fiber neuropathy affects thinly myelinated A-delta and unmyelinated C fibers, so burning pain, altered thermal sensation, or autonomic symptoms can coexist with normal routine studies. Reduced intraepidermal nerve-fiber density on a standardized skin biopsy supports structural small fiber loss when interpreted with appropriate reference values and clinical findings. It does not identify the cause or quantify all autonomic functions; etiologic and function-specific assessments remain separate.
Apply it
A patient has burning feet, reduced pin and temperature sensation, preserved vibration and strength, and normal routine studies. Consider objective small fiber assessment, then investigate plausible causes rather than interpreting a positive biopsy as proof of diabetes or autoimmunity.
Common pitfall: Normal routine studies neither exclude peripheral sensory disease nor independently prove small fiber neuropathy. Reduced skin fiber density also cannot establish etiology or justify immunotherapy by itself.
EFNS/PNS guideline on skin biopsy in the diagnosis of small fiber neuropathy
30.How should metabolic and toxic causes be investigated in a distal polyneuropathy?
A distal symmetric sensory or sensorimotor pattern should prompt a focused search for common systemic and exposure-related causes. Diabetes, nutritional deficiency, alcohol exposure, and neurotoxic medications are important considerations. The official outline specifically includes vitamin B12 and copper deficiency, excess vitamin B6, and medications such as metronidazole, nitrofurantoin, isoniazid, and chemotherapy. Establish the exposure, dose, duration, and temporal relationship rather than assigning causation from a medication list. Small fiber loss on biopsy confirms neither a metabolic nor a toxic cause.
Apply it
A patient with burning feet takes several supplements and has received prolonged antimicrobial therapy. Obtain exact ingredient and medication histories, evaluate relevant metabolic and nutritional causes, and check whether symptom timing and phenotype fit a suspected exposure.
Common pitfall: Diabetes does not explain every neuropathy in a person with diabetes. Rapid progression, marked asymmetry, substantial proximal weakness, or long-tract signs should reopen the differential rather than be absorbed into a routine distal neuropathy label.
Neuromuscular Medicine Certification Content Specifications · EFNS/PNS guideline on skin biopsy in the diagnosis of small fiber neuropathy · EAN/PNS guideline on diagnosis and treatment of CIDP — Second revision
Neuromuscular junction transmission disorders16–20%
31.Which weakness pattern suggests myasthenia gravis?
Myasthenia gravis impairs postsynaptic neuromuscular transmission and characteristically causes fluctuating, fatigable weakness. Ocular, bulbar, neck, limb, and respiratory muscles may be affected, while sensation and pupillary responses are generally preserved. Weakness that worsens with sustained activity and improves with rest supports the pattern, but the diagnosis requires appropriate corroboration. Fixed sensory loss, prominent autonomic failure, or a purely length-dependent weakness pattern should prompt consideration of another localization or a coexisting condition.
Apply it
A patient develops diplopia late in the day and nasal speech after prolonged conversation, with normal pupils and sensation. Examine fatigability and pursue appropriate antibody and electrophysiological testing rather than attributing the symptoms to a distal neuropathy.
Common pitfall: General tiredness is not the same as demonstrable fatigable weakness. The distribution, examination, and corroborating tests distinguish myasthenic dysfunction from nonspecific fatigue.
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
32.Why does antibody subtype matter in myasthenia gravis?
Antibody findings help define biologically and therapeutically relevant subgroups of myasthenia gravis. AChR-antibody-positive and MuSK-antibody-positive disease differ in their typical clinical associations and evidence supporting particular interventions. For example, evidence supporting elective thymectomy in selected nonthymomatous generalized disease applies to AChR-antibody-positive patients, while the guidance does not support thymectomy for MuSK-associated disease without another indication. Negative routine antibody testing does not alone exclude myasthenia when clinical and electrophysiological evidence remains convincing.
Apply it
Two patients have generalized fatigable weakness, but one has AChR antibodies and the other MuSK antibodies. Use the subtype when discussing treatment evidence rather than assuming that a thymectomy recommendation transfers unchanged between them.
Common pitfall: Seronegativity is not proof against myasthenia, and seropositivity does not eliminate the need to match symptoms and examination to a plausible neuromuscular transmission disorder.
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
33.How are repetitive stimulation and jitter interpreted operationally?
For low-frequency repetitive stimulation, use stable supramaximal stimulation, immobilization, and adequate temperature. At 3 Hz, calculate amplitude decrement as 100 × (first CMAP minus fourth or fifth CMAP) divided by the first CMAP. The [AAEM diagnostic practice parameter](https://onlinelibrary.wiley.com/doi/10.1002/mus.1139) recognizes a reproducible 10% decrement as abnormal. Test clinically involved muscles; facial or proximal muscles may be more informative than an unaffected distal hand muscle. Jitter measures variation in transmission timing and requires reference limits appropriate to the muscle, electrode, activation method, age, and laboratory. The [2025 diagnostic consensus study](https://pubmed.ncbi.nlm.nih.gov/40129481/) proposed combinations of abnormalities across two RNS studies, an RNS and a jitter study, or two jitter studies; these are proposed clinical criteria, not an official examination rule.
Apply it
With technically stable 3-Hz stimulation, the first CMAP is 10.0 mV and the fourth is 8.5 mV: decrement is 15%. Reproduction in an involved facial muscle supports transmission failure. If a laboratory's validated mean-jitter upper limit for the exact method is 30 microseconds, a mean of 38 exceeds that limit; 30 is an illustrative laboratory value, not a universal cutoff.
Common pitfall: Movement and submaximal stimulation can mimic decrement. Increased jitter can accompany reinnervation, neuropathy, myopathy, or botulinum toxin effects and does not independently establish autoimmune myasthenia or its antibody subtype.
34.How are impending and manifest myasthenic crises treated?
Rapid bulbar or respiratory deterioration requires monitored admission, assessment of airway protection, and timely ventilatory support. Normal oxygen saturation does not exclude dangerous hypoventilation. IVIg and plasma exchange are short-term treatments used alongside respiratory support, not alternatives to it. Selection considers urgency, availability, venous access and hemodynamic tolerance for exchange, and renal dysfunction, thrombosis risk, or hypersensitivity with IVIg. Expert consensus considers plasma exchange faster acting, although trials suggest broadly comparable efficacy. Corticosteroids and other sustained immunotherapy address longer-term control; corticosteroids can initially worsen weakness, so rescue treatment may precede their initiation in a vulnerable patient. The [international consensus guidance](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/) distinguishes these immediate and sustained treatment roles.
Apply it
A patient with myasthenia develops choking on secretions, a weak cough, and worsening breathing during infection. Arrange monitored airway and ventilatory assessment, treat the trigger, and begin IVIg or plasma exchange after evaluating selection factors. Plan sustained immunotherapy without relying on its slower effect to rescue ventilation.
Common pitfall: Do not wait for desaturation or use corticosteroid escalation alone for impending respiratory failure. Initial steroid worsening and increased airway secretions from cholinesterase inhibitors can complicate acute management.
International consensus guidance for management of myasthenia gravis: Executive summary - PMC
35.Which patients have evidence supporting elective thymectomy?
The consensus update recommends considering thymectomy early in nonthymomatous generalized AChR-antibody-positive myasthenia in adults aged 18–50 to improve clinical outcomes and reduce immunotherapy requirements. Elective surgery should occur when the patient is stable enough for the procedure. Thymoma introduces a separate tumor-related indication and management pathway. The evidence should not be generalized automatically to ocular-only disease, MuSK-associated disease, or every older patient, because the populations and strength of supporting evidence differ.
Apply it
A 34-year-old with recently diagnosed generalized AChR-positive myasthenia has no thymoma and is clinically stable. Discuss elective thymectomy's expected role in long-term disease management rather than presenting it as an immediate rescue treatment.
Common pitfall: Thymectomy is not an acute treatment for impending respiratory failure. Stabilization and appropriate crisis management take precedence over elective surgery intended for longer-term benefit.
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
36.Which medications merit particular caution in myasthenia gravis?
Fluoroquinolones, macrolides, aminoglycosides, and beta-blockers have been associated with worsening myasthenia. Statins also have very infrequent reports of new or aggravated myasthenia. These risks require drug-specific assessment rather than a universal prohibition: consider infection severity, microbiological susceptibility, safer effective alternatives, prior reactions, and current bulbar and respiratory reserve. Infection itself can precipitate deterioration. When a potentially worsening drug is necessary, coordinate prescribing and arrange monitoring appropriate to the patient's risk.
Apply it
A patient with myasthenia and limited respiratory reserve is prescribed ciprofloxacin for a bacterial infection. Review culture results and effective alternatives with the prescriber. If the drug remains necessary, plan close observation for new dysphagia, weak cough, or breathing difficulty while treating the infection promptly.
Common pitfall: A caution list does not mean withholding essential treatment regardless of circumstances. Previous tolerance also does not guarantee safety during an infection when neuromuscular reserve may be reduced.
Statins: very infrequent reports of myasthenia gravis - GOV.UK · International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
37.How does Lambert-Eaton syndrome impair transmission?
Lambert-Eaton myasthenic syndrome is a presynaptic disorder associated with antibodies against voltage-gated calcium channels. Reduced calcium entry limits acetylcholine release, causing weakness and often autonomic symptoms. Repeated activation can increase available presynaptic calcium and transiently improve transmission, explaining facilitation. Proximal leg weakness, reduced reflexes, dry mouth, and postactivation improvement favor this pattern over typical postsynaptic myasthenia. Electrophysiological confirmation evaluates the response to activation rather than relying on symptoms alone.
Apply it
A patient has difficulty rising from chairs, dry mouth, and reduced tendon reflexes that become more evident after brief contraction. Investigate a presynaptic transmission disorder using appropriate motor studies and activation testing rather than assuming a primary muscle disease.
Common pitfall: Fatigability occurs in more than one transmission disorder. Autonomic symptoms, reflex behavior, and facilitation help distinguish Lambert-Eaton syndrome from typical autoimmune myasthenia.
38.Why does Lambert-Eaton syndrome trigger malignancy evaluation?
Lambert-Eaton myasthenic syndrome has an important association with small-cell lung carcinoma. A compatible presynaptic transmission disorder therefore requires evaluation for an underlying malignancy as well as management of weakness and autonomic symptoms. Neurological symptoms may lead to recognition of a previously unsuspected tumor. Smoking history and other clinical risk factors inform concern, but absence of constitutional symptoms does not remove the association. A negative initial investigation should be interpreted within an appropriate ongoing specialist assessment.
Apply it
A long-term smoker is diagnosed with Lambert-Eaton syndrome after presenting with proximal weakness and dry mouth. Explain why tumor evaluation is part of the neurological care plan even though there is no cough or weight loss.
Common pitfall: Treating the weakness alone can miss an associated cancer. The absence of respiratory symptoms does not make small-cell lung carcinoma irrelevant to this syndrome.
39.Which clinical pattern should raise immediate concern for botulism?
Botulism causes presynaptic failure of acetylcholine release and typically produces acute cranial neuropathies followed by symmetric descending flaccid paralysis. Diplopia, ptosis, dysphagia, dysarthria, and autonomic features may precede limb weakness. Sensation and mental status are generally preserved unless another complication intervenes. Pupillary abnormalities can help distinguish botulism from typical myasthenia, but their absence does not exclude it. Compatible clinical findings require urgent respiratory assessment and public-health consultation rather than waiting for laboratory confirmation.
Apply it
Two people develop blurred vision, dysphagia, dry mouth, and descending weakness after sharing home-preserved food. Recognize a possible botulism cluster, assess ventilation, and initiate urgent consultation while arranging appropriate diagnostic specimens and treatment.
Common pitfall: A food exposure history can support the diagnosis but is not mandatory. Wound and other forms of botulism may present without a shared meal.
CDC — Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021
40.Why must botulism antitoxin precede laboratory confirmation?
Botulism antitoxin neutralizes toxin that has not yet bound to nerve terminals. It can limit further progression but does not reverse paralysis already produced by bound toxin, so treatment benefit depends on timely administration. Diagnostic testing supports confirmation and public-health investigation, but its turnaround should not delay antitoxin when clinical suspicion warrants treatment. Recovery requires restoration of neuromuscular function over time, and patients may still need prolonged ventilatory, swallowing, and rehabilitation support after antitoxin is given.
Apply it
A patient with a convincing botulism syndrome is becoming weaker while confirmatory testing remains pending. Seek antitoxin urgently and continue respiratory monitoring, explaining that treatment aims to prevent additional injury rather than immediately restore established muscle strength.
Common pitfall: Persistent paralysis after antitoxin does not prove treatment failure. Antitoxin cannot detach toxin already bound at the neuromuscular junction or instantly repair affected terminals.
CDC — Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021
Muscle disorders24–26%
41.How does a DMPK expansion produce DM1 and anticipation?
Myotonic dystrophy type 1 is caused by a CTG repeat expansion in DMPK and follows autosomal dominant inheritance. Expanded-repeat RNA disrupts RNA processing, contributing to a multisystem disorder rather than isolated muscle stiffness. Repeat instability can produce anticipation, with earlier or more severe disease in a subsequent generation. Congenital DM1 is particularly associated with maternal transmission. Repeat size helps characterize the disorder but cannot precisely predict an individual patient's complete severity or future course.
Apply it
A mildly affected mother with grip myotonia has an infant with severe hypotonia and respiratory difficulty. Consider congenital DM1 and explain repeat expansion and anticipation while arranging molecular confirmation and coordinated family counseling and assessment.
Common pitfall: A mildly affected parent does not guarantee mild disease in a child. Anticipation makes family severity an unreliable ceiling for the next generation's manifestations.
42.Why does DM1 require cardiac surveillance and specific perioperative planning?
DM1 can cause cardiac conduction disease and arrhythmias independently of skeletal muscle weakness severity. Syncope, presyncope, and palpitations warrant prompt assessment, and ongoing cardiac surveillance remains necessary in ambulatory patients. Respiratory weakness, sleep-related breathing problems, dysphagia, and gastrointestinal dysfunction add perioperative vulnerability. Before sedation or anesthesia, communicate the diagnosis and individual cardiopulmonary and swallowing findings, review respiratory-depressant medication risks, and plan postoperative observation and support.
Apply it
A patient with mild distal weakness reports unexplained fainting and daytime sleepiness before an elective procedure. Arrange cardiac and respiratory assessment and share the findings with anesthesia rather than judging procedural risk from walking ability or the apparent severity of myotonia.
Common pitfall: Walking ability is not a cardiac or respiratory risk screen. Completion of a procedure does not end the period of perioperative risk, and focusing only on muscle stiffness misses major complications.
43.Which findings suggest a dystrophinopathy and guide confirmation?
Duchenne muscular dystrophy is an X-linked disorder caused by absent or insufficient functional dystrophin, compromising muscle-fiber stability. Early proximal weakness, difficulty climbing stairs, a Gowers maneuver, and markedly elevated CK should prompt evaluation. The [DMD care considerations](https://pmc.ncbi.nlm.nih.gov/articles/PMC5869704/) recommend DMD deletion/duplication testing, followed by sequencing when needed; muscle dystrophin analysis can help when molecular testing remains unresolved. Glucocorticoid treatment and rehabilitation require coordinated assessment, including bone and adrenal risks. Anticipatory [cardiac and respiratory care](https://pmc.ncbi.nlm.nih.gov/articles/PMC5889091/) is essential because cardiomyopathy and ventilatory impairment can progress beyond what limb function alone reveals.
Apply it
A young boy uses his hands to climb up his thighs when standing and has elevated aminotransferases. Measure CK and investigate dystrophinopathy rather than assuming primary liver disease. A molecular diagnosis also enables family counseling and assessment of at-risk relatives.
Common pitfall: A Gowers maneuver indicates proximal weakness rather than a unique diagnosis. Female carriers can require medical follow-up, including cardiac assessment; carrier status should not be treated as universally asymptomatic.
44.What biochemical and respiratory findings define Pompe disease?
Pompe disease results from deficiency of lysosomal acid alpha-glucosidase, encoded by GAA, causing lysosomal glycogen accumulation. This autosomal recessive disorder has infantile and later-onset presentations. Later-onset disease may resemble a limb-girdle myopathy, but diaphragmatic weakness, orthopnea, or nocturnal hypoventilation can be prominent despite preserved walking. Diagnosis uses appropriate enzyme testing and molecular analysis, with confirmation of screening results and consideration of pseudodeficiency. Positional respiratory measurements and sleep-related assessment can expose impairment missed by limb examination.
Apply it
An ambulatory adult has progressive proximal weakness and cannot sleep comfortably lying flat. Obtain appropriate GAA enzyme and molecular testing while assessing diaphragmatic and nocturnal respiratory function. Respiratory support remains important alongside disease-directed treatment.
Common pitfall: Pompe is a lysosomal glycogen disorder, not muscle glycogen phosphorylase deficiency. Neither a limb-girdle pattern nor a screening enzyme result alone establishes the diagnosis, and preserved ambulation does not establish normal ventilation.
45.How do the phenotype and molecular mechanism identify facioscapulohumeral dystrophy?
FSHD typically affects facial, scapular-stabilizing, and humeral muscles early, often producing difficulty closing the eyes, scapular winging, and impaired arm elevation. Relative deltoid sparing helps distinguish the pattern from a generic proximal myopathy. The [AAN/AANEM guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC4520817/) emphasizes this selective distribution. FSHD1 involves contraction of the D4Z4 repeat array at chromosome 4q35 in a permissive genetic context. The [primary genetic study](https://pubmed.ncbi.nlm.nih.gov/20724583/) demonstrated a permissive polyadenylation signal that stabilizes DUX4 transcripts, linking the repeat configuration to inappropriate DUX4 expression.
Apply it
A patient has scapular winging, weak eye closure, and humeral weakness with relatively preserved deltoids. Pursue FSHD-specific repeat and haplotype assessment rather than assuming that ordinary sequencing of a dystrophy panel will answer the repeat-array question.
Common pitfall: A short D4Z4 array must be interpreted with its chromosomal and permissive haplotype context. Scapular winging alone is not specific and also occurs with focal nerve lesions and neuralgic amyotrophy.
46.Why does CRIM status matter in infantile Pompe disease?
Cross-reactive immunologic material status describes whether endogenous GAA protein is detectable, not whether that protein has adequate enzyme activity. CRIM-negative infants are especially vulnerable to developing high sustained antibodies against replacement enzyme, potentially compromising treatment effectiveness. Determining CRIM status informs immune-tolerance planning around enzyme replacement. CRIM-positive status does not eliminate all antibody risk. The distinction is immunological and must not be mistaken for a direct classification of how much functional enzyme activity remains.
Apply it
An infant has confirmed Pompe disease with no detectable endogenous GAA protein. Coordinate CRIM-informed immune management with enzyme replacement planning rather than treating the absent protein result as merely another measure of muscle disease severity.
Common pitfall: Detectable protein is not the same as functional protein. CRIM positivity can coexist with severe enzyme deficiency, while CRIM negativity specifically raises treatment-related immune concerns.
47.What mechanism produces the second wind in McArdle disease?
McArdle disease results from muscle glycogen phosphorylase deficiency, impairing access to stored muscle glycogen during activity. Early exercise can therefore cause disproportionate fatigue, pain, and contractures. After reducing intensity or briefly resting, some patients experience a second wind as delivery and use of circulating fuels improve. This characteristic change in exercise tolerance helps distinguish the disorder from other causes of exertional symptoms. Molecular confirmation addresses PYGM, rather than the GAA defect responsible for Pompe disease.
Apply it
A runner repeatedly develops painful fatigue in the first minutes of exercise but can continue more comfortably after slowing down. Ask specifically about this reproducible second wind and investigate a muscle glycogen breakdown disorder.
Common pitfall: Second wind is not permission to push through severe pain. Sustained strenuous activity during the initial energy deficit can provoke muscle injury and rhabdomyolysis.
48.How does CPT II deficiency differ from McArdle disease?
Myopathic CPT II deficiency impairs long-chain fatty-acid oxidation and typically causes episodes of myalgia, weakness, and rhabdomyolysis after prolonged exercise, fasting, or febrile illness. A [physiological study](https://onlinelibrary.wiley.com/doi/full/10.1002/ana.20320) demonstrated failure to increase long-chain fat oxidation adequately during prolonged low-intensity exercise. McArdle disease instead often produces symptoms within the first minutes of activity and a characteristic second wind because stored muscle glycogen cannot be used normally. Trigger duration and fasting sensitivity therefore help distinguish lipid from glycogen energy failure.
Apply it
One patient develops painful early exercise intolerance relieved by slowing; another has recurrent myoglobinuria after long hikes undertaken while fasting. Consider PYGM-related disease in the first and CPT2-related disease in the second, then confirm with appropriate biochemical and molecular testing.
Common pitfall: Exertional rhabdomyolysis is not specific to a glycogen disorder. Between episodes, a patient with a lipid-oxidation defect may appear well; a symptom-free clinic visit does not negate the trigger history.
GeneReviews — Glycogen Storage Disease Type V · Neuromuscular Medicine Certification Content Specifications
49.How can exercise and rhabdomyolysis risk be managed in McArdle disease?
Complete inactivity is not the goal in McArdle disease. Individually adapted aerobic conditioning, gradual warm-up, and recognition of the second wind can improve functional capacity. Abrupt intense exercise, heavy sustained isometric effort, and continuing through severe pain increase injury risk. Severe pain, weakness, swelling, or dark urine after exertion warrants assessment for rhabdomyolysis, renal injury, and electrolyte disturbances. Absence of dark urine does not exclude muscle breakdown. An exercise plan should account for baseline conditioning and prior episodes, with clear stopping rules.
Apply it
Develop a gradual aerobic plan for a patient avoiding all walking through fear of injury. Separately explain that severe thigh pain and cola-colored urine after carrying furniture require urgent assessment rather than waiting for a second wind.
Common pitfall: Universal rest promotes deconditioning, but pushing through contractures is unsafe. Safe activity counseling and recognition of an acute muscle-injury episode are complementary parts of management.
50.Which weakness distribution and complications should suggest inclusion body myositis?
Inclusion body myositis often causes slowly progressive, asymmetric weakness with disproportionate involvement of finger flexors and quadriceps. Loss of grip, knee buckling, difficulty rising, and falls are useful clues. Dysphagia can cause aspiration, weight loss, and reduced quality of life and requires direct assessment independently of limb strength. Integrate age, course, distribution, and pathology. Conventional immunosuppression generally does not produce the sustained benefit expected in several other inflammatory myopathies; mobility, swallowing, nutritional, rehabilitation, and selected procedural care remain central.
Apply it
An older adult has years of knee buckling and difficulty opening jars, with deep finger-flexor weakness exceeding shoulder weakness. Evaluate for IBM and directly ask about food sticking and meal duration, even if the patient focuses on falls.
Common pitfall: Distal weakness does not automatically localize to nerve, and biopsy inflammation does not guarantee steroid responsiveness. Stable limb function also does not establish safe swallowing.
Inclusion body myositis: Update on the diagnostic and therapeutic landscape
51.Which IBM biopsy findings require integration with the clinical phenotype?
IBM pathology can include rimmed vacuoles, endomysial inflammation with invasion of nonnecrotic fibers, and abnormal protein accumulation, including p62-positive inclusions and cytoplasmic TDP-43 aggregates. These inflammatory and degenerative findings must be interpreted together. Invasion of nonnecrotic fibers can overlap with other inflammatory myopathies and is not independently specific. A [clinicopathological study](https://pubmed.ncbi.nlm.nih.gov/17881720/) identified patients with an IBM clinical pattern whose biopsies lacked canonical IBM features, demonstrating the limitations of biopsy-only classification. A [primary pathological study](https://pubmed.ncbi.nlm.nih.gov/35044790/) also documents rimmed vacuoles, p62 inclusions, and TDP-43 abnormalities.
Apply it
A biopsy reports endomysial invasion but no rimmed vacuoles in a patient with years of asymmetric quadriceps and deep finger-flexor weakness. Seek clinicopathological review, including appropriate stains and assessment of sampling, rather than diagnosing polymyositis solely from inflammatory invasion.
Common pitfall: Absent rimmed vacuoles or characteristic aggregates do not automatically exclude IBM because abnormalities may be patchy or incompletely developed. Conversely, rimmed vacuoles alone occur in other myopathies and do not establish IBM without clinical correlation.
Inclusion body myositis: Update on the diagnostic and therapeutic landscape
52.Which clinical and pathological findings distinguish dermatomyositis from IBM?
Dermatomyositis commonly combines symmetric proximal weakness with characteristic skin findings: heliotrope discoloration around the eyes and Gottron papules or sign over extensor joints. Perifascicular atrophy means smaller fibers concentrated at the edges of muscle fascicles; it differs from IBM's rimmed vacuoles and selective finger-flexor–quadriceps pattern. The [2017 EULAR/ACR classification study](https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40320) incorporates characteristic rashes, weakness patterns, enzymes, and biopsy findings into a probability-based framework. Classification criteria support consistent research grouping and should not be treated as a standalone diagnostic substitute.
Apply it
A patient develops subacute difficulty rising and lifting the arms, violaceous eyelid changes, and papules over the knuckles. Connect this skin–muscle pattern with a biopsy showing perifascicular atrophy rather than categorizing every inflammatory biopsy as polymyositis or IBM.
Common pitfall: Perifascicular atrophy and endomysial invasion describe different morphological patterns. A nonspecific enzyme elevation or the word inflammation cannot replace the examination of skin, weakness distribution, and actual biopsy architecture.
53.When does statin-associated weakness suggest anti-HMGCR autoimmunity?
Anti-HMGCR autoimmune myopathy is associated with antibodies targeting HMG-CoA reductase and can present with substantial proximal weakness and muscle enzyme elevation. Persistence or progression after statin withdrawal distinguishes concern for an immune-mediated process from a simple self-limited toxic effect. The original study identified HMGCR as an autoantigen in this syndrome. Clinical assessment, antibody testing, and other appropriate studies establish the diagnosis; statin exposure alone neither proves autoimmunity nor explains every episode of muscle pain.
Apply it
A patient stops a statin because of proximal weakness, but weakness and marked enzyme elevation persist. Investigate immune-mediated necrotizing myopathy, including anti-HMGCR testing, rather than repeatedly reassuring the patient that drug withdrawal has completed the evaluation.
Common pitfall: Common statin-associated muscle symptoms are not automatically autoimmune myopathy. Persistent objective weakness and biochemical abnormalities provide the reason to investigate the rarer immune-mediated syndrome.
Autoantibodies against HMG-CoA reductase in patients with statin-associated autoimmune myopathy
54.How does chloride-channel myotonia differ mechanistically from a multisystem dystrophy?
Nondystrophic myotonia can arise from a primary skeletal-muscle ion-channel disorder, including dysfunction of the ClC-1 chloride channel encoded by CLCN1. Reduced chloride conductance destabilizes the sarcolemma, allowing repetitive muscle-fiber action potentials that produce stiffness and delayed relaxation. DM1 can produce a similar chloride-channel physiological disturbance through abnormal ClC-1 RNA splicing, but its DMPK repeat expansion also causes a multisystem dystrophy. Cataracts, progressive characteristic weakness, conduction disease, and inheritance history help distinguish these diagnoses; molecular testing identifies the underlying cause.
Apply it
A patient has longstanding stiffness and electrical myotonia without the characteristic multisystem findings of DM1. Consider nondystrophic myotonia and appropriate channel-gene testing rather than treating the EMG finding as proof of a DMPK expansion.
Common pitfall: A shared sarcolemmal mechanism does not establish a shared genetic disease. The ClC-1 splicing-correction experiment in mouse DM models demonstrates a mechanism; it does not establish an approved human treatment for all myotonic disorders.
JCI - Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy · GeneReviews — Myotonic Dystrophy Type 1 · Neuromuscular Medicine Certification Content Specifications
55.How can mitochondrial myopathy escape a routine blood-based evaluation?
Mitochondrial respiratory-chain defects impair oxidative energy production and can cause severe exercise intolerance without a classic glycogen second wind or a multisystem syndrome. A [primary cytochrome-b study](https://www.nejm.org/doi/full/10.1056/NEJM199909303411404) identified muscle mitochondrial-DNA mutations associated with complex III deficiency and exercise intolerance; the mutations were not detected in the patients' tested peripheral-blood samples. Most had resting lactic acidosis. This demonstrates why tissue distribution matters and why a negative blood result does not exclude every mitochondrial myopathy. It does not mean that all mitochondrial disorders require muscle biopsy or share the same inheritance.
Apply it
A patient has severe unexplained exercise intolerance, persistent lactate elevation, and nondiagnostic blood testing without a second-wind history. Consider a respiratory-chain disorder and select further molecular, tissue, and biochemical assessment according to the phenotype and prior test coverage.
Common pitfall: Lactate elevation alone is nonspecific. Likewise, absence of a maternal family history or negative blood mitochondrial testing cannot independently exclude a sporadic, muscle-restricted mitochondrial defect.
Hyper-excitability disorders1–3%
56.Which EMG findings support Isaacs syndrome?
Isaacs syndrome is a peripheral nerve hyperexcitability disorder that can cause continuous muscle activity, stiffness, cramps, and visible rippling. Needle EMG may demonstrate myokymic discharges and high-frequency neuromyotonic discharges, reflecting repetitive motor axon activity rather than voluntary contraction. The electrical pattern helps distinguish the syndrome from ordinary cramps, isolated fasciculations, and primary muscle myotonia. Evaluation should also consider associated autoimmune or neoplastic disease according to the complete clinical presentation rather than treating the discharges as an isolated incidental finding.
Apply it
A patient has persistent calf rippling and stiffness even while resting. Needle EMG shows grouped repetitive motor-unit bursts and neuromyotonic discharges, supporting peripheral nerve hyperexcitability and prompting evaluation for an associated underlying condition.
Common pitfall: Neuromyotonia and myotonia describe different electrical mechanisms. Repetitive motor axon firing should not be interpreted automatically as a primary muscle membrane channel disorder.
57.How does Isaacs syndrome differ from stiff-person syndrome?
Isaacs syndrome localizes hyperexcitability to peripheral motor nerves and is supported by myokymic or neuromyotonic discharges. Stiff-person syndrome instead characteristically involves impaired central inhibitory motor control, with axial or proximal stiffness and stimulus-triggered painful spasms. Both can produce continuous muscle activity, so the clinical distribution and electrophysiological pattern matter. Distinguishing the physiological source prevents the broad symptom of stiffness from becoming a diagnosis and helps direct associated autoimmune evaluation and specialist management.
Apply it
Compare persistent distal muscle rippling with neuromyotonic discharges against marked axial stiffness and sound-triggered spasms. Use the combined phenotype and EMG pattern to choose between peripheral nerve hyperexcitability and a central stiffness syndrome.
Common pitfall: Continuous muscle activity alone is insufficient for classification. The discharge type, anatomical distribution, and stimulus sensitivity determine whether the dominant mechanism is peripheral or central.
Autonomic dysfunction in neuromuscular diseases1–3%
58.Why can GBS dysautonomia require monitoring beyond limb strength?
GBS can disrupt autonomic control, causing substantial blood-pressure fluctuations, tachycardia, bradyarrhythmias, gastrointestinal dysmotility, or urinary dysfunction. These complications can be clinically dangerous and need assessment independently of the motor examination. Monitoring intensity should reflect the patient's overall course and autonomic findings rather than walking ability alone. Abrupt heart-rate or pressure changes require careful evaluation because both the disease and other acute medical causes may contribute, and an apparently improving motor examination does not eliminate autonomic risk.
Apply it
A hospitalized patient with GBS develops alternating tachycardia and bradycardia with large blood-pressure swings. Escalate monitored assessment and review potential contributors rather than regarding the changes as harmless anxiety because limb weakness has stopped progressing.
Common pitfall: Motor stabilization does not guarantee autonomic stabilization. Discharging or reducing observation solely because strength has plateaued can overlook a separate source of acute risk.
EAN/PNS Guideline on diagnosis and treatment of Guillain–Barré syndrome
59.How should sensory and autonomic small fiber findings be separated?
Small fibers include sensory and autonomic components, but a test of one component does not fully characterize the other. Reduced intraepidermal nerve-fiber density supports cutaneous small fiber loss; it does not quantify the severity of cardiovascular, sweating, gastrointestinal, or bladder dysfunction. Autonomic symptoms therefore require their own clinical assessment and, when appropriate, function-specific testing. Likewise, an autonomic complaint does not establish a particular neuropathy cause. Structural evidence, functional evidence, and etiologic reasoning answer different clinical questions.
Apply it
A patient with biopsy-supported small fiber neuropathy develops orthostatic symptoms. Assess the hemodynamic pattern and relevant medications or systemic contributors instead of assuming that the skin biopsy has already established the mechanism and severity of those symptoms.
Common pitfall: Do not use skin fiber density as a substitute for autonomic function assessment. A structural result cannot quantify every physiological consequence of small fiber disease.
EFNS/PNS guideline on skin biopsy in the diagnosis of small fiber neuropathy
Questions not associated with a specific neuromuscular disorder1–2%
60.How is motor nerve conduction velocity calculated?
Motor conduction velocity across a tested segment equals the distance between proximal and distal stimulation sites divided by the difference between their motor onset latencies. Subtraction removes the distal components shared by both responses, including neuromuscular transmission and muscle activation time. For 0.24 meters and a latency difference of 0.004 seconds, velocity is 60 meters per second. Accurate distance, onset identification, adequate stimulation, and consistent units are essential; the calculation alone does not define a universal normal cutoff.
Apply it
Proximal and distal onset latencies are 8.0 and 4.0 milliseconds, with stimulation sites 24 centimeters apart. Convert the distance and time consistently, then calculate 0.24 divided by 0.004 to obtain 60 meters per second.
Common pitfall: Dividing by the proximal latency alone includes shared distal delay and gives the wrong segmental velocity. The historical formula source does not establish current universal reference limits.
NIOSH — Performing Motor and Sensory Neuronal Conduction Studies in Adult Humans
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Prioritize muscle and peripheral nerve disorders while maintaining substantial motor neuron and neuromuscular junction coverage.
- Build localization from weakness distribution, reflexes, sensory responses, and strategically selected muscles before interpreting imaging.
- Distinguish axonal loss, demyelination, transmission failure, myopathic injury, and peripheral nerve hyperexcitability using discriminating findings.
- Apply operational Gold Coast and EAN/PNS criteria while recognizing that individual findings cannot replace the complete diagnostic framework.
- Compare CMT1A, HNPP, amyloid neuropathy, CIDP, painful multifocal axonal neuropathy, and metabolic or toxic neuropathy using chronology, physiology, and systemic clues.
- Recognize treatment-changing boundaries: MMN versus ALS, motor CIDP versus typical CIDP, GBS versus CIDP, and autoimmune versus self-limited statin injury.
- Connect SMN1, SMN2, SOD1, DMPK, PMP22, DMD, DUX4, CLCN1, GAA, PYGM, and CPT2 findings to mechanism, counseling, and appropriate management.
- Compare dystrophinopathy, FSHD, dermatomyositis, IBM, mitochondrial disease, and glycogen or lipid-metabolism disorders rather than treating every myopathy as symmetric proximal weakness.
- Practise respiratory, bulbar, cardiac, autonomic, and nutritional decisions independently of apparent limb weakness severity.
- Apply cross-cutting competencies through accessible communication, objective response measurement, multidisciplinary planning, and distinctions among trial evidence, guideline recommendations, and regulatory indications.
A practical preparation plan
1. Map the full official scope
Read both blueprint dimensions and the [official detailed outline](https://abpn.org/wp-content/uploads/Neuromuscular-Medicine-Certification-Content-Specifications.pdf), which defines the full examination scope. Mark topics absent from this selective guide, including additional mononeuropathies, congenital disorders, dystrophies, and root/cord conditions, and add them to your study schedule.
2. Construct localization comparisons
For each weakness pattern, compare motor neuron, root, cord, plexus, nerve, junction, and muscle explanations. State the sensory response, reflex, distribution, and electrodiagnostic finding that would most strongly change your localization.
3. Study mechanisms alongside management
Pair each disease mechanism with one diagnostic test and one consequential management decision. Practise diagnostic thresholds, decrement calculations, GBS treatment windows, ALS pharmacotherapy, and myasthenic-crisis treatment selection. Include disease-specific treatment exceptions.
4. Complete the twenty independent questions
Choose one answer before reviewing each explanation. For every error, identify whether the problem was localization, chronology, mechanism, interpretation, or treatment evidence, then revisit the relevant official-outline topic.
5. Use spaced recall and objective reasoning
Review the flashcards in spaced sessions. Explain each answer aloud and supply a contrasting diagnosis. Recalculate conduction velocity without notes and rehearse interpreting supportive tests that cannot establish etiology by themselves.
6. Integrate safety and patient priorities
Rehearse cases involving orthopnea, dysphagia, syncope, dysautonomia, medication selection, and communication impairment. Explain the physiological concern, immediate assessment need, multidisciplinary contribution, and how the patient's preferences shape longer-term management.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABPMR — Neuromuscular Medicine
- ABPN — Neuromuscular Medicine
- Neuromuscular Medicine Certification Content Specifications
- Supplementary tables including criteria for diagnosing ALS
- GeneReviews — Spinal Muscular Atrophy
- Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial
- NICE NG42 — Motor neurone disease: assessment and management
- AANEM — Cervical Radiculopathy/Brachial Plexopathy
- A standardized ultrasound approach in neuralgic amyotrophy
- GeneReviews — Hereditary Neuropathy with Liability to Pressure Palsies
- Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies
- Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders
- EAN/PNS guideline on diagnosis and treatment of CIDP — Second revision
- EFNS/PNS guideline on skin biopsy in the diagnosis of small fiber neuropathy
- International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
- NLM MeSH — Lambert-Eaton Myasthenic Syndrome
- CDC — Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021
- GeneReviews — Myotonic Dystrophy Type 1
- Inclusion body myositis: Update on the diagnostic and therapeutic landscape
- GeneReviews — Pompe Disease
- GeneReviews — Glycogen Storage Disease Type V
- Autoantibodies against HMG-CoA reductase in patients with statin-associated autoimmune myopathy
- Isaacs syndrome: A review
- EAN/PNS Guideline on diagnosis and treatment of Guillain–Barré syndrome
- NIOSH — Performing Motor and Sensory Neuronal Conduction Studies in Adult Humans
- Neuromuscular_Medicine_CERT_Format_and_Scoring.pdf
- Recommendations | Motor neurone disease: assessment and management | Guidance | NICE
- JCI - Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy
- Statins: very infrequent reports of myasthenia gravis - GOV.UK
- 5-EAN-guideline-amyotrophic-lateral-sclerosis-2024.pdf
- International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update - PMC
- International consensus guidance for management of myasthenia gravis: Executive summary - PMC
- zivkovic-et-al-2020-muscle-nerve.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.